Black Diamond Therapeutics, Inc.

General ticker "BDTX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $202.7M (TTM average)

Black Diamond Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -13.4%.

Estimated limits based on current volatility of 2.7%: low 1.59$, high 1.68$

Factors to consider:

  • Earnings expected soon, date: 2025-05-08 bmo
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [1.29$, 3.47$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.10$, 2.93$]

Financial Metrics affecting the BDTX estimates:

  • Negative: Non-GAAP EPS, $ of -1.27 <= 0.04
  • Negative: Operating cash flow per share per price, % of -31.82 <= 1.79
  • Negative: negative Net income
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: negative Operating income
  • Positive: Shareholder equity ratio, % of 67.91 > 63.75
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Industry earnings per price (median), % of -27.42 <= 0

Similar symbols

Short-term BDTX quotes

2025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-301.21.41.61.822.22.42.62.8
Price $

Long-term BDTX plot with estimates

1234567Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.4−0.3−0.2−0.10
BDTXS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $92.83MM $86.46MM $78.78MM
Operating Income $-92.83MM $-86.46MM $-78.78MM
Non-Operating Income $1.66MM $4.02MM $9.11MM
R&D Expense $64.44MM $59.35MM $51.31MM
Income(Loss) $-91.17MM $-82.44MM $-69.68MM
Profit(Loss)* $-84.52MM $-82.44MM $-69.68MM
Stockholders Equity $115.69MM $116.74MM $83.28MM
Assets $156.25MM $158.57MM $122.64MM
Operating Cash Flow $-85.08MM $-66.72MM $-62.30MM
Capital expenditure $0.19MM $0.03MM $0.00MM
Investing Cash Flow $53.37MM $16.35MM $16.97MM
Financing Cash Flow $0.18MM $71.93MM $25.55MM
Earnings Per Share** $-2.33 $-1.88 $-1.27

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.